Quick Answer
C4 Therapeutics, Inc. reported Diluted EPS of $1.27 per share (loss) for fiscal year 2025.
C4 Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.27 | +16.4% |
| 2024 | -$1.52 | +43.1% |
| 2023 | -$2.67 | -1.9% |
| 2022 | -$2.62 | -44.0% |
| 2021 | -$1.82 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.44 | -25.7% | -18.9% |
| June 30, 2025 | -$0.37 | -42.3% | +0.0% |
| March 31, 2025 | -$0.37 | +9.8% | -5.7% |
| September 30, 2024 | -$0.35 | +36.4% | -34.6% |
| June 30, 2024 | -$0.26 | +64.4% | +36.6% |
| March 31, 2024 | -$0.41 | +42.3% | +25.5% |
| September 30, 2023 | -$0.55 | +15.4% | +24.7% |
| June 30, 2023 | -$0.73 | -30.4% | -2.8% |
- C4 Therapeutics, Inc. showed an increase of +16.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, C4 Therapeutics, Inc.’s diluted eps has grown by 30.2% (from $1.82 per share (loss) to $1.27 per share (loss)).
- The most recent figure is from C4 Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: